Tag Archives: CSF Tau

Further Dementia Diagnostic Test Accuracy Systematic Review Protocols (Cochrane Database)

Posted on August 29, 2014 by Dementia and Elderly Care News

Summary This is an additional list of diagnostic testing-related protocols, further to the Cochrane Dementia and Cognitive Improvement Group (CDCIG) Diagnostic Test Accuracy (DTA) protocols and protocol templates listed earlier in Generic Protocol(s) for Diagnostic Test Accuracy Reviews in Dementia … Continue reading →

Recent Brain Research / Neurology-Related Systematic Reviews and Meta-Analyses

Posted on August 19, 2014 by Dementia and Elderly Care News

Summary Recent reviews and meta-analyses on neurology-related topics are listed below. Some of these articles may be available freely (according to local circumstances). A suitable Athens password, a journal subscription or payment for access are required to obtain the full-text … Continue reading →

Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Social Workers (mostly), International, Systematic Reviews | Tagged Adult-Onset Spinocerebellar Ataxias, Biomarkers, Cerebrospinal Fluid (CSF), Charles Bonnet Syndrome, Chemokine Receptors, Chemokines, Chronic Traumatic Encephalopathy, Cognitive Decline, CSF Tau, DaTSCAN, Dementia with Lewy Bodies, DLB: Dementia with Lewy Bodies, Dorsal Angular Gyrus, Frontotemporal Dementia (FTD), Homocysteine, Hyperconnectivity, Neurodegeneration, Neurodegenerative Diseases, Neurological Disease, Neurological Research, Neuropathology, Neurosonology, Perturbed Iron Distribution, Posterior Middle Temporal Cortex, Primary Progressive Aphasia (PPA) | Leave a comment

Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)

Posted on August 2, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia. The accuracy of … Continue reading →

Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK | Tagged Aß40, Aß42, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer's Association, Alzheimer's Disease and Related Disorders Association (Now the Alzheimer's Association), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Asymptomatic Alzheimer’s Disease, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood-Based Biomarkers, Cambridge Institute of Public Health, Cambridge Institute of Public Health: Cambridge University, Candidate Blood Proteome Markers, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Improvement Group, Cochrane Register of Diagnostic Test Accuracy Studies, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, Conversion to Dementia From Prodromal Disease, CSF Aß Levels, CSF Aβ, CSF Biomarkers, CSF Tau, Dementia Screening, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), Diagnostic Test Accuracy, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, Fluid and Imaging Biomarkers, Imperial College London, Institute of Public Health: University of Cambridge, β-amyloid, β-Amyloid 1-42 (Aβ42), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), National Institute of Neurological and Communicative Disorders and Stroke, Neurodegeneration, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Plasma Biomarkers, Plasma Proteins, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Progression of Mild Cognitive Impairment to Dementia, Systematic Reviews and Meta-Analyses, Transition from Cognitive Impairment to Dementia, University of Birmingham, University of Cambridge, University of Oxford, University of Oxford: Radcliffe Department of Medicine, University of Western Australia, US Alzheimer's Association, Western Australian Centre for Health and Ageing (WACHA) | Leave a comment

Alzheimer’s Disease Biomarkers: Updated Hypothetical Model (Lancet Neurology)

Posted on April 18, 2014 by Dementia and Elderly Care News

Summary A hypothetical model of the major biomarkers of Alzheimer’s Disease, published by the same authors in 2010, has been updated in the light of new evidence. Full Text Link Reference Jack, CR. Jr. Knopman, DS. [and] Jagust, WJ. [et … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews | Tagged Aβ, Aβopathy, Aβopathy Acceleration of Antecedent Tauopathy, Alzheimer's Disease: Hypothetical Model(s), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Brain Beta Amyloid Load, Brain Deposition of Amyloid, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Clearance of Amyloid Beta Protein, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, CSF Aβ, CSF Biomarkers, CSF Tau, Department of Biomedical Statistics and Informatics: Mayo Clinic (Rochester), Department of Neurology: Mayo Clinic (Rochester), Department of Neurosciences: University of California-San Diego, Department of Radiology: Mayo Clinic (Rochester), Early Detection of Alzheimer’s Disease, Early Diagnosis of Alzheimer's Disease, Fluid and Imaging Biomarkers, Indexing Subjects by Time, Inter-Subject Variability, β-amyloid, β-Amyloid 1-42 (Aβ42), Lancet Neurology, Longitudinal Population Studies of Diagnostic Biomarkers, Mayo Clinic: Rochester, Metabolic FDG-PET, Molecular PIB-PET, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, Ordering of Alzheimer's Disease Biomarkers, Pathophysiological Processes in Alzheimer’s Disease, Positron Emission Tomography (PET), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Proteinopathies, School of Public Health and Helen Wills Neuroscience Institute: University of California, Sequence of Pathological Events in Alzheimer’s Disease, Structural MRI, Tau, Tau Pathology, Tau Protein, Temporal Evolution of Alzheimer’s Disease Biomarkers, Temporal Ordering of Biomarkers, Test to Detect Early-Stage Alzheimer’s Disease, United States, University of California, University of Pathology and Laboratory Medicine and Institute on Aging: University of Pennsylvania, University of Pennsylvania School of Medicine, USA, Veterans Affairs and University of California | Leave a comment

Early Diagnosis of Alzheimer’s Disease Using Spinal Fluid? (NHS Choices / Cell Reports)

Posted on March 27, 2014 by Dementia and Elderly Care News

Summary A recent diagnostic study has investigated the possibility of diagnosing Alzheimer’s Disease, years before disease onset, using cerebrospinal fluid (CSF). The technique for identifying people with Alzheimer’s Disease would be based on detecting very small amounts of abnormal (misfolded) … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged Aβ-PMCA, Alzheimer's Association, Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amprion Inc., Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Assessment and Diagnosis, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biochemical Diagnosis of Alzheimer's Disease, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Carlo Besta Neurological Institute, CART Foundation, Cell Reports, Centro Dino Ferrari, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, CSF, CSF Aβ, CSF Aβ(1-42), CSF Biomarkers, CSF Tau, Cyclic Amplification of Amyloid-Beta Misfolding, Dementia Screening, Department of Neurology: University of Texas Medical School at Houston, Detection of Synthetic Ab Oligomers by Ab-PMCA, Differential Diagnosis, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Screening, Improving Diagnosis, IRCC Ospedale Policlinico, IRCCS Foundation, Italian Ministry of Health, Italy, Lumbar Punctures, Milan, Misfolded Aβ Oligomers, Misfolded Proteins, Mitchell Center for Alzheimer's Disease and Related Brain Disorders: University of Texas Medical School at Houston, Mitchell Foundation, MIUR, Neurodegeneration, Neurodegenerative Diseases, Neurology Unit: Università di Milano, Non-AD Neurodegenerative Diseases (NANDs), Nondegenerative Neurological Diseases (NNDs), Protein Misfolding Cyclic Ampliﬁcation (PMCA), Screening, Spinal Fluid, Timely Diagnosis, Università di Milano, University of Texas Medical School at Houston, USA | Leave a comment

Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)

Posted on March 2, 2014 by Dementia and Elderly Care News

Summary Accurate and sensitive tools are required for the early detection / diagnosis of Alzheimer’s Disease, particularly to assist research. Alzheimer’s Disease clinical trials make increasing use of biomarkers, particularly neuroimaging markers and cerebrospinal fluid (CSF) biomarkers obtained via invasive … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Quick Insights | Tagged Aβ42, Alzheimer's Disease Neuroimaging Initiative (ADNI) Cohort, Alzheimer’s Disease Clinical Trials, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Argentina, Australia, Autonomous Systems Laboratory: Universidad Politécnica de Madrid, Avid’s AV-45 (Florbetapir), Belgium, Beta-Amyloid, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomedical Engineering Laboratory: Okayama University, BM List of AD Biomarkers, BM=(w o τ aβ hc fc tac), Canada, Cerebrospinal Fluid (CSF), Chile, Clearance of Amyloid Beta Protein, Compliance with Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Computed Tomography (CT), CSF, CSF Aβ, CSF Aβ(1-42), CSF Tau, Default-Mode Network (DMN), Dementia Research, Denmark, Disease Progression, Finland, Fludeoxyglucose FDG PET, Flutemetamol (18F), fMRI, France, Frontiers in Aging Neuroscience, Functional Connectivity, Functional Magnetic Resonance Imaging (fMRI), GE’s Flutametamol, Germany, Global Alzheimer’s Association Interactive Network (GAAIN), Hippocampus, Hyperphosphorylated Tau, India, Israel, Italy, β-amyloid, β-Amyloid 1-42 (Aβ42), Japan, Lumbar Puncture Compliance, Lumbar Punctures, Magnetic Resonance Imaging (MRI), Magnetic Resonance Spectroscopy (MRS), Measurement of Treatment Effects, Mexico, Morphometric Analysis, Network-Based Biomarkers, Neurodegeneration, Neurofibrillary Tangles (NFTs), Neuroimaging, Neuroimaging of Dementia, Neuroimaging Tools, o (Orientation), Okayama University, Poland, Positron Emission Tomography (PET), Quintiles, Resting-State fMRI (R-fMRI), South Africa, Spain, Sweden, Tactile Biomarker (tac), Taiwan, Tau Pathology, Tau Protein, Universidad Politécnica de Madrid, USA, Volumetric MRI, w (Word Recognition) | Leave a comment

Brain Scans Distinguish Between Dementia Types (BBC News / Neurology)

Posted on December 31, 2012 by Dementia and Elderly Care News

Summary Scientists at the University of Pennsylvania believe they may have discovered how to distinguish between different types of dementia without the need for invasive lumbar puncture tests to obtain cerebrospinal fluid (csf). Alzheimer’s and frontotemporal dementia share similar features and symptoms and can … Continue reading →

Posted in BBC News, Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest | Tagged Amyloid Beta, Amyloid Beta Protein, Assessment and Diagnosis, Beta-Amyloid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, CSF, CSF Aβ, CSF Tau, CSF tt/Aβ Ratios, Diagnosis and Assessment, Diagnosis and Screening: Frontotemporal Dementia, Diagnosis of Alzheimer's Disease, Diagnostic Errors, Diagnostic Markers, Early Differential Diagnosis, Frontotemporal Dementia, Frontotemporal Lobar Degeneration (FTLD), FTLD: Frontotemporal Lobar Degeneration, β-amyloid, Magnetic Resonance Imaging (MRI), MRI, MRI Scans, Tau, Tau Protein, Total Tau (T-tau), University of Pennsylvania | Leave a comment

Tag Archives: CSF Tau

Further Dementia Diagnostic Test Accuracy Systematic Review Protocols (Cochrane Database)

Alzheimer’s Disease Biomarkers: Updated Hypothetical Model (Lancet Neurology)

Biomarker Assessments in Alzheimer’s Disease Clinical Trials (Quintiles / Frontiers in Aging Neuroscience)

Brain Scans Distinguish Between Dementia Types (BBC News / Neurology)

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites